Reducing endothelial NOS activation and interstitial fluid pressure with n-3 PUFA offset tumor chemoresistance

Carcinogenesis

Volumn 33, Issue 2, 2012, Pages 260-267

  Kornfeld, Sophie ^a,b,e   Goupille, Caroline ^a,c   Vibet, Sophie ^a   Chevalier, Stephan ^a   Pinet, Amandine ^a   Lebeau, Justine ^a   Tranquart, François ^d,e   Bougnoux, Philippe ^a,c   Martel, Eric ^b   Maurin, Anne ^b   Richard, Serge ^b   Champeroux, Pascal ^b   Mahéo, Karine ^a  

^a SFED   (France)

^b Centre de Recherches Biologiques   (France)

^c CHU BRETONNEAU   (France)

^d UNIVERSITÉ DE TOURS   (France)

^e Bracco Suisse SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID; DOCETAXEL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EVANS BLUE; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST TUMOR; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TISSUE PRESSURE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR RESISTANCE; TUMOR VASCULARIZATION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84856577045     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr274     Document Type: Article

References (52)

1. Biondo, P.D. et al (2008) The potential for treatment with dietary longchain polyunsaturated n-3 fatty acids during chemotherapy. J. Nutr. Biochem., 19, 787-796.
2. Calviello, G. et al (2009) Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies. Nutr. Cancer, 61, 287-301.
3. Bougnoux, P. et al (2010) Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. Prog. Lipid Res., 49, 76-86.
4. Bougnoux, P. et al (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br. J. Cancer, 101, 1978-1985.
5. Murphy, R.A. et al (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer, 117, 3774-3780.
6. Vibet, S. et al (2008) Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic. Biol. Med., 44, 1483-1491.
7. Colas, S. et al (2004) Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int. J. Cancer, 109, 449-454.
8. Rose, D.P. et al (1999) Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int. J. Oncol., 15, 1011-1015.
9. Colas, S. et al (2006) Sensitization by dietary docosahexaenoic acid of rat mammary carcinoma to anthracycline: a role for tumor vascularization. Clin. Cancer Res., 12, 5879-5886.
10. Gerber, H.P. et al (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res., 65, 671-680.
11. Hu, L. et al (2002) Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am. J. Pathol., 161, 1917-1924.
12. Lee, C.G. et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res., 60, 5565-5570.
13. Jain, R.K (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62.
14. Jain, R.K. et al (2010) Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol., 7, 653-664.
15. Fukumura, D. et al (2007) Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell Biochem., 101, 937-949.
16. Fukumura, D. et al (2001) Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc. Natl Acad. Sci. USA, 98, 2604-2609.
17. Cairns, R. et al (2006) Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol. Cancer Res., 4, 61-70.
18. Wildiers, H. et al (2003) Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br. J. Cancer, 88, 1979-1986.
19. Pietras, K. et al (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res., 62, 5476-5484.
20. Curti, B.D. et al (1993) Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment. Cancer Res., 53, 2204-2207.
21. Milosevic, M. et al (2001) Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor oxygen measurements. Cancer Res., 61, 6400-6405.
22. Chajes, V. et al (1995) Membrane fatty acids of breast carcinoma: contribution of host fatty acids and tumor properties. Int. J. Cancer, 63, 169-175.
23. Lhuillery, C. et al (1995) Time-course study of adipose tissue fatty acid composition during mammary tumor growth in rats with controlled fat intake. Nutr. Cancer, 24, 299-309.
24. Denis, F. et al (2002) In vivo quantitation of tumour vascularisation assessed by Doppler sonography in rat mammary tumours. Ultrasound Med. Biol., 28, 431-437.
25. Broillet, A. et al (2005) Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. Acad. Radiol., 12 (suppl.), S28-S33.
26. Schnell, C.R. et al (2008) Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging. Cancer Res., 68, 6598-6607.
27. Loadman, P.M. et al (1999) Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin. Cancer Res., 5, 3682-3688.
28. Bougnoux, P. et al (1994) Alpha-linolenic acid content of adipose breast tissue: a host determinant of the risk of early metastasis in breast cancer. Br. J. Cancer, 70, 330-334.
29. Geng, B. et al (2007) Hydrogen sulfide downregulates the aortic L-arginine/nitric oxide pathway in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 293, R1608-R1618.
30. Dimmeler, S. et al (2000) Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett., 477, 258-262.
31. Tsuzuki, T. et al (2007) Anti-angiogenic effects of conjugated docosahexaenoic acid in vitro and in vivo. Biosci. Biotechnol. Biochem., 71, 1902-1910.
32. Tsuji, M. et al (2003) Docosapentaenoic acid (22:5, n-3) suppressed tubeforming activity in endothelial cells induced by vascular endothelial growth factor. Prostaglandins Leukot. Essent. Fatty Acids, 68, 337-342.
33. Wiig, H. et al (1982) Interstitial fluid pressure in DMBA-induced rat mammary tumours. Scand. J. Clin. Lab. Invest., 42, 159-164.
34. Ferretti, S. et al (2005) Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin. Cancer Res., 11, 7773-7784.
35. Ferretti, S. et al (2009) Tumor interstitial fluid pressure as an early-response marker for anticancer therapeutics. Neoplasia, 11, 874-881.
36. Heldin, C.H. et al (2004) High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer, 4, 806-813.
37. Gade, T.P. et al (2009) Imaging intratumoral convection: pressuredependent enhancement in chemotherapeutic delivery to solid tumors. Clin. Cancer Res., 15, 247-255.
38. Dickson, P.V. et al (2007) Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res., 13, 3942-3950.
39. Tong, R.T. et al (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res., 64, 3731-3736.
40. Griffon-Etienne, G. et al (1999) Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res., 59, 3776-3782.
41. Su, Y. et al (2002) Microtubule-active agents modify nitric oxide production in pulmonary artery endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol., 282, L1183-L1189.
42. Giustiniani, J. et al (2009) Basal endothelial nitric oxide synthase (eNOS) phosphorylation on Ser(1177) occurs in a stable microtubuleand tubulin acetylation-dependent manner. Exp. Cell Res., 315, 3509-3520.
43. Fulton, D. et al (2001) Post-translational control of endothelial nitric oxide synthase: why isn't calcium/calmodulin enough? J. Pharmacol. Exp. Ther., 299, 818-824.
44. Bauer, P.M. et al (2003) Compensatory phosphorylation and proteinprotein interactions revealed by loss of function and gain of function mutants of multiple serine phosphorylation sites in endothelial nitric-oxide synthase. J. Biol. Chem., 278, 14841-14849.
45. Fukumura, D. et al (2006) The role of nitric oxide in tumour progression. Nat. Rev. Cancer, 6, 521-534.
46. Thibeault, S. et al (2010) S-nitrosylation of beta-catenin by eNOS-derived NO promotes VEGF-induced endothelial cell permeability. Mol. Cell., 39, 468-476.
47. Murohara, T. et al (1998) Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation, 97, 99-107.
48. Gratton, J.P. et al (2003) Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell, 4, 31-39.
49. Netti, P.A. et al (1999) Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc. Natl Acad. Sci. USA, 96, 3137-3142.
50. Germain, E. et al (2003) Anthracycline-induced cardiac toxicity is not increased by dietary omega-3 fatty acids. Pharmacol. Res., 47, 111-117.
51. Kubes, P. et al (1992) Nitric oxide modulates microvascular permeability. Am. J. Physiol., 262, H611-H615.
52. Baldwin, A.L. et al (1998) Inhibition of nitric oxide synthesis increases venular permeability and alters endothelial actin cytoskeleton. Am. J. Physiol., 274, H1776-H1784.